Graybug Vision Presents Preclinical Results for GB-401, a Potential Sustained-Delivery Treatment of up to Six Months for Primary Open Angle Glaucoma, at the American Glaucoma Society Annual Meeting
February 28, 2020 07:00 ET | Graybug Vision, Inc.
REDWOOD CITY, Calif., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc., a biopharmaceutical company focused on developing transformative medicines to treat diseases of the retina and optic...
Normal_Epi 9mm
Optovue Highlights World’s First OCTA Metrics and Corneal Measurement Method at AAO 2018
October 25, 2018 09:00 ET | Optovue, Incorporated
Blood Vessel Measurement Technology Helps Doctors Manage Eye Diseases CHICAGO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Optovue, the global leader in the development of optical coherence tomography (OCT)...
GrayBug, LLC Appoints Michael O'Rourke as President & CEO
October 28, 2013 11:32 ET | GrayBug
BALTIMORE, Oct. 28, 2013 (GLOBE NEWSWIRE) -- GrayBug, LLC, a company that focuses on the development of innovative injectable drug delivery systems to more effectively treat eye diseases, has...